NEOG logo

Neogen Corporation Stock Price

NasdaqGS:NEOG Community·US$2.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

NEOG Share Price Performance

US$9.34
4.36 (87.55%)
US$12.00
Fair Value
US$9.34
4.36 (87.55%)
22.2% undervalued intrinsic discount
US$12.00
Fair Value
Price US$9.34
AnalystConsensusTarget US$12.00
AnalystLowTarget US$11.00
AnalystHighTarget US$13.00

NEOG Community Narratives

·
Fair Value US$12 22.2% undervalued intrinsic discount

NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
·
Fair Value US$11 15.1% undervalued intrinsic discount

Declining Demand And Integration Woes Will Dampen Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$13 28.2% undervalued intrinsic discount

Digital Transformation And Protein Demand Will Unlock Testing Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$13
28.2% undervalued intrinsic discount
Profit Margin
11.88%
Future PE
37.54x
Price in 2029
US$16.46
US$11
15.1% undervalued intrinsic discount
Profit Margin
12.2%
Future PE
30.62x
Price in 2029
US$13.94

Trending Discussion

Updated Narratives

NEOG logo

NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook

Fair Value: US$13 28.2% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEOG logo

NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside

Fair Value: US$11 15.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEOG logo

NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential

Fair Value: US$12 22.2% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with adequate balance sheet.

1 Risk
2 Rewards

Neogen Corporation Key Details

US$870.6m

Revenue

US$477.0m

Cost of Revenue

US$393.6m

Gross Profit

US$1.0b

Other Expenses

-US$608.8m

Earnings

Last Reported Earnings
Feb 28, 2026
Next Reporting Earnings
n/a
-2.80
45.21%
-69.94%
37.8%
View Full Analysis

About NEOG

Founded
1981
Employees
2974
CEO
Mikhael Nassif
WebsiteView website
www.neogen.com

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Recent NEOG News & Updates

Seeking Alpha Jun 27

Neogen: Still A Difficult Story

Summary Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest, and recent divestments were at low sales multiples. Q3 results were mixed: core food safety sales grew 4%, the animal segment fell 8% due to a supplier issue, and adjusted EBITDA margin rose to 22.8%. The $160M genomics business sale to Zoetis reduces net debt below $500M but was completed at only 1.5x sales, reflecting lagging margins and limited immediate value creation. Pro forma sales are now ~$800M, with realistic earnings estimates of $0.30-$0.45/share; organic growth and margin improvement remain critical for re-rating. Read the full article on Seeking Alpha
Narrative Update Jun 23

NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook

Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.

Recent updates

No updates